Add Yahoo as a preferred source to see more of our stories on Google. For men facing the return of prostate cancer, a new combination therapy may offer a much longer break before the disease comes ...
A new drug combination may benefit men whose prostate cancer has returned after primary surgery or radiation therapy. Pairing enzalutamide, an androgen receptor blocker, with the hormone therapy drug ...
Imperial College London investigators compared focal therapy with prostate removal surgery for men with prostate cancer that returned after radiotherapy. Matched analyses estimated 10-year ...
A novel immunotherapy combination is proving to be both safe and manageable for patients with prostate cancer, according to updated Phase 1 trial data presented at the 2026 ASCO Genitourinary Cancers ...
New research in the February 2026 issue of JNCCN-Journal of the National Comprehensive Cancer Network found that incorporating information from prostate-specific membrane antigen (PSMA) PET/CT scans ...
More than 70% of patients with biochemically recurrent prostate cancer remained metastasis-free 5 years after PSMA PET/CT-guided salvage radiation therapy. Whole-pelvis radiation significantly ...
MedPage Today on MSN
Bubbles of Prostate Cancer Info; Cancer Drug Tops Moneymakers; Small Kidney Tumors
News, features, and commentary about cancer-related issues ...
Clinical node involvement on preoperative PSMA-PET predicts radiographic recurrence for pN1 prostate cancer patients following RP/PLND.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results